Russell Investments Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $144M | Buy |
230,151
+2,065
| +0.9% | +$1.41M | 0.13% | 146 |
|
|
2026
Q1 | $176M | Buy |
228,086
+6,996
| +3% | +$5.36M | 0.19% | 94 |
|
|
2025
Q4 | $171M | Sell |
221,090
-7,738
| -3% | -$5.25M | 0.19% | 99 |
|
|
2025
Q3 | $129M | Buy |
228,828
+55,019
| +32% | +$31.1M | 0.15% | 138 |
|
|
2025
Q2 | $91.1M | Buy |
173,809
+27,069
| +18% | +$15.1M | 0.12% | 183 |
|
|
2025
Q1 | $93.1M | Buy |
146,740
+9,532
| +7% | +$6.56M | 0.13% | 167 |
|
|
2024
Q4 | $97.7M | Buy |
137,208
+7,944
| +6% | +$6.67M | 0.13% | 151 |
|
|
2024
Q3 | $136M | Buy |
129,264
+2,516
| +2% | +$2.8M | 0.2% | 94 |
|
|
2024
Q2 | $133M | Sell |
126,748
-1,763
| -1% | -$1.71M | 0.21% | 85 |
|
|
2024
Q1 | $124M | Buy |
128,511
+7,481
| +6% | +$7.11M | 0.2% | 102 |
|
|
2023
Q4 | $106M | Sell |
121,030
-5,171
| -4% | -$4.26M | 0.19% | 108 |
|
|
2023
Q3 | $104M | Buy |
126,201
+352
| +0.3% | +$277K | 0.21% | 92 |
|
|
2023
Q2 | $90.4M | Sell |
125,849
-2,653
| -2% | -$2.05M | 0.17% | 118 |
|
|
2023
Q1 | $105M | Sell |
128,502
-6,275
| -5% | -$4.73M | 0.21% | 101 |
|
|
2022
Q4 | $97.2M | Sell |
134,777
-32,205
| -19% | -$23.8M | 0.2% | 105 |
|
|
2022
Q3 | $115M | Buy |
166,982
+6,369
| +4% | +$4.01M | 0.25% | 71 |
|
|
2022
Q2 | $95.2M | Sell |
160,613
-26,577
| -14% | -$17.3M | 0.19% | 115 |
|
|
2022
Q1 | $131M | Sell |
187,190
-24,865
| -12% | -$15.7M | 0.23% | 85 |
|
|
2021
Q4 | $134M | Buy |
212,055
+6,112
| +3% | +$3.76M | 0.21% | 91 |
|
|
2021
Q3 | $125M | Buy |
205,943
+17,105
| +9% | +$10.6M | 0.21% | 95 |
|
|
2021
Q2 | $105M | Buy |
188,838
+24,724
| +15% | +$12.5M | 0.18% | 114 |
|
|
2021
Q1 | $77.5M | Buy |
164,114
+33,307
| +25% | +$16.2M | 0.14% | 159 |
|
|
2020
Q4 | $63.1M | Buy |
130,807
+3,964
| +3% | +$2.14M | 0.12% | 184 |
|
|
2020
Q3 | $71.4M | Sell |
126,843
-9,649
| -7% | -$5.85M | 0.15% | 143 |
|
|
2020
Q2 | $84.8M | Buy |
136,492
+16,325
| +14% | +$9.27M | 0.19% | 111 |
|
|
2020
Q1 | $58.6M | Buy |
120,167
+6,783
| +6% | +$2.8M | 0.15% | 138 |
|
|
2019
Q4 | $42.6M | Sell |
113,384
-45,670
| -29% | -$15.4M | 0.08% | 293 |
|
|
2019
Q3 | $44.1M | Buy |
159,054
+61,276
| +63% | +$18.1M | 0.09% | 287 |
|
|
2019
Q2 | $30.6M | Sell |
97,778
-20,747
| -18% | -$6.91M | 0.06% | 397 |
|
|
2019
Q1 | $48.6M | Buy |
118,525
+28,802
| +32% | +$11.9M | 0.09% | 263 |
|
|
2018
Q4 | $33.4M | Sell |
89,723
-16,945
| -16% | -$6.2M | 0.07% | 299 |
|
|
2018
Q3 | $43.1M | Buy |
106,668
+18,742
| +21% | +$7.13M | 0.08% | 264 |
|
|
2018
Q2 | $30.3M | Sell |
87,926
-95,630
| -52% | -$29.9M | 0.06% | 353 |
|
|
2018
Q1 | $62.8M | Buy |
183,556
+14,776
| +9% | +$5.14M | 0.11% | 224 |
|
|
2017
Q4 | $64.6M | Buy |
168,780
+4,084
| +2% | +$1.65M | 0.11% | 210 |
|
|
2017
Q3 | $73.6M | Buy |
164,696
+18,443
| +13% | +$8.78M | 0.13% | 184 |
|
|
2017
Q2 | $71.9M | Sell |
146,253
-8,844
| -6% | -$3.87M | 0.13% | 180 |
|
|
2017
Q1 | $60.1M | Buy |
155,097
+13,539
| +10% | +$5.02M | 0.11% | 214 |
|
|
2016
Q4 | $52.9M | Buy |
+141,558
| New | +$53.8M | 0.1% | 220 |
|
Other funds holding REGN
Russell Investments Group's REGN Position: Q2 2026 in Review
Russell Investments Group increased its Regeneron Pharmaceuticals (REGN) stake by 0.91% in Q2 2026, buying an estimated $1.41M and bringing the position to 230,151 shares worth $144M. The position accounts for 0.13% of the portfolio, ranked #146.
Russell Investments Group first reported a position in REGN in Q4 2016 and has held it in 39 quarters since. The position peaked at $176M in Q1 2026. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Russell Investments Group held 230,151 shares of Regeneron Pharmaceuticals worth $144M as of Q2 2026.
- Russell Investments Group bought 2,065 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.41M.
- Regeneron Pharmaceuticals made up 0.13% of Russell Investments Group's portfolio in Q2 2026, its #146 holding.
- Russell Investments Group first reported a position in Regeneron Pharmaceuticals in Q4 2016 and has held it in 39 quarters since.
- Russell Investments Group's Regeneron Pharmaceuticals position peaked at $176M in Q1 2026.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.